+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Peanut Allergy - Pipeline Review, H2 2018

  • ID: 4658179
  • Drug Pipelines
  • 117 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aimmune Therapeutics Inc
  • Allergy Therapeutics Plc
  • ASIT Biotech SA
  • BioLingus AG
  • Cambridge Allergy Ltd
  • F. Hoffmann-La Roche Ltd
  • MORE
Peanut Allergy - Pipeline Review, H2 2018

Summary

This disease pipeline guide, Peanut Allergy - Pipeline Review, H2 2018, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

Report Highlights

This disease pipeline guide, Peanut Allergy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 5, 7, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 2 and 1 molecules, respectively.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aimmune Therapeutics Inc
  • Allergy Therapeutics Plc
  • ASIT Biotech SA
  • BioLingus AG
  • Cambridge Allergy Ltd
  • F. Hoffmann-La Roche Ltd
  • MORE
Introduction

Report Coverage

Peanut Allergy - Overview

Peanut Allergy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Peanut Allergy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peanut Allergy - Companies Involved in Therapeutics Development

Adverum Biotechnologies Inc

Aimmune Therapeutics Inc

Alfacyte Ltd

Allergy Therapeutics Plc

AnaptysBio Inc

ASIT Biotech SA

Astellas Pharma Inc

BioLingus AG

BlueWillow Biologics Inc

Cambridge Allergy Ltd

DBV Technologies SA

F. Hoffmann-La Roche Ltd

HAL Allergy BV

Inimmune Corp

Intrommune Therapeutics

Regeneron Pharmaceuticals Inc

Sanofi

Peanut Allergy - Drug Profiles

AK-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aldesleukin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Peanut Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Peanut Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Peanut Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANN-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-0892 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CA-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DBV-712 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Peanut Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dupilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etokimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HALMPE-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INT-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pnt-ASIT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polyvac Peanut - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVX-108 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-439794 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCV-204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Peanut Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Peanut Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to target TLR for Peanut Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTC-064 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peanut Allergy - Dormant Projects

Peanut Allergy - Discontinued Products

Peanut Allergy - Product Development Milestones

Featured News & Press Releases

Sep 12, 2018: DBV Technologies announces positive DSMB review of Part A of phase III study in peanut-allergic toddlers

Sep 06, 2018: Intrommune Therapeutics completes Pre-IND meeting with FDA on INT301 for peanut allergy

Aug 07, 2018: Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th

Jul 26, 2018: DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

Jun 11, 2018: Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO

May 30, 2018: Aimmune Therapeutics Announces New Pan-European Study Showing Significant Psychosocial Burden Associated With Peanut Allergy

May 29, 2018: DBV Technologies Shows Commitment to the Development of Treatments for Food Allergies at EAACI 2018

May 28, 2018: Aimmune Therapeutics Announces New Clinical Data on AR101 for Peanut Allergy at the 2018 EAACI Congress

May 16, 2018: DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors

May 15, 2018: Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018

May 15, 2018: Intrommune Therapeutics Submits Pre-IND Meeting Request to the U.S. FDA for INT301, Its Peanut Allergy Oral Mucosal Immunotherapy Drug Candidate, During Food Allergy Awareness Week

May 08, 2018: DBV Technologies to Present New Clinical Data of Viaskin Peanut at the 2018 EAACI Meeting

Apr 24, 2018: Intrommune Therapeutics to Present at Eighth Annual BioNJ BioPartnering Conference

Mar 26, 2018: AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients

Mar 04, 2018: Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Peanut Allergy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Peanut Allergy - Pipeline by Adverum Biotechnologies Inc, H2 2018

Peanut Allergy - Pipeline by Aimmune Therapeutics Inc, H2 2018

Peanut Allergy - Pipeline by Alfacyte Ltd, H2 2018

Peanut Allergy - Pipeline by Allergy Therapeutics Plc, H2 2018

Peanut Allergy - Pipeline by AnaptysBio Inc, H2 2018

Peanut Allergy - Pipeline by ASIT Biotech SA, H2 2018

Peanut Allergy - Pipeline by Astellas Pharma Inc, H2 2018

Peanut Allergy - Pipeline by BioLingus AG, H2 2018

Peanut Allergy - Pipeline by BlueWillow Biologics Inc, H2 2018

Peanut Allergy - Pipeline by Cambridge Allergy Ltd, H2 2018

Peanut Allergy - Pipeline by DBV Technologies SA, H2 2018

Peanut Allergy - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Peanut Allergy - Pipeline by HAL Allergy BV, H2 2018

Peanut Allergy - Pipeline by Inimmune Corp, H2 2018

Peanut Allergy - Pipeline by Intrommune Therapeutics, H2 2018

Peanut Allergy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Peanut Allergy - Pipeline by Sanofi, H2 2018

Peanut Allergy - Dormant Projects, H2 2018

Peanut Allergy - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Peanut Allergy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Adverum Biotechnologies Inc
  • Aimmune Therapeutics Inc
  • Alfacyte Ltd
  • Allergy Therapeutics Plc
  • AnaptysBio Inc
  • ASIT Biotech SA
  • Astellas Pharma Inc
  • BioLingus AG
  • BlueWillow Biologics Inc
  • Cambridge Allergy Ltd
  • DBV Technologies SA
  • F. Hoffmann-La Roche Ltd
  • HAL Allergy BV
  • Inimmune Corp
  • Intrommune Therapeutics
  • Regeneron Pharmaceuticals Inc
  • Sanofi
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4658179
Adroll
adroll